研究单位：[1]Institute of Hematology & Blood Diseases Hospital, China[2]Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC[3]First Hospital of China Medical University[4]Hebei Medical University Fourth Hospital[5]Chengdu Shangjin Nanfu Hospital[6]Affiliated Cancer Hospital & Institute of Guizhou Medical University[7]The Second Affiliated Hospital of Dalian Medical University[8]Xuanwu Hospital, Beijing[9]The Affiliated Ganzhou Hospital of Nanchang University[10]Beijing Tongren Hospital[11]The First Affiliated Hospital of Dalian Medical University[12]The First Hospital of Jilin University[13]People's Hospital of Zhengzhou University[14]The First Affiliated Hospital of Bengbu Medical University[15]The Second Affiliated Hospital of Kunming Medical University[16]The First Affiliated Hospital of Nanchang University[17]The Second Affiliated Hospital of Harbin Medical University[18]Shengjing Hospital[19]Peking University Third Hospital[20]First Affiliated Hospital of Harbin Medical University[21]China-Japan Friendship Hospital[22]Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC,Tianjin,Tianjin,China,300020[23]Affiliated Cancer Hospital & Institute of Guangzhou Medical University
This is a prospective clinical study to evaluate the safety and efficacy of GVM±R in patients with relapsed or refractory aggressive non-Hodgkin's lymphoma (NHL).
